rs121909147
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM2PM5PP3PP5_Very_Strong
The ENST00000503393.8(SH3BP2):āc.1253C>Gā(p.Pro418Arg) variant causes a missense change. The variant allele was found at a frequency of 0.00000139 in 1,435,998 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P418L) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000503393.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SH3BP2 | NM_001122681.2 | c.1253C>G | p.Pro418Arg | missense_variant | 9/13 | ENST00000503393.8 | NP_001116153.1 | |
SH3BP2 | NM_001145856.2 | c.1424C>G | p.Pro475Arg | missense_variant | 9/13 | NP_001139328.1 | ||
SH3BP2 | NM_001145855.2 | c.1337C>G | p.Pro446Arg | missense_variant | 9/13 | NP_001139327.1 | ||
SH3BP2 | NM_003023.4 | c.1253C>G | p.Pro418Arg | missense_variant | 9/13 | NP_003014.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SH3BP2 | ENST00000503393.8 | c.1253C>G | p.Pro418Arg | missense_variant | 9/13 | 1 | NM_001122681.2 | ENSP00000422168 | P2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000139 AC: 2AN: 1435998Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 711922
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Fibrous dysplasia of jaw Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 25, 2023 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Pro418 amino acid residue in SH3BP2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17321449, 23298620, 28644570). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects SH3BP2 function (PMID: 21794028, 22153076, 22153077, 24916406, 25144740). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SH3BP2 protein function. ClinVar contains an entry for this variant (Variation ID: 7548). This missense change has been observed in individual(s) with cherubism (PMID: 11381256, 14577811, 18596838, 30236129). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with arginine, which is basic and polar, at codon 418 of the SH3BP2 protein (p.Pro418Arg). - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2001 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Jul 01, 2022 | This sequence change in SH3BP2 is predicted to replace proline with arginine at codon 418, p.(Pro418Arg). The proline residue is highly conserved (100 vertebrates, UCSC), and is located within the RSPPDG peptide sequence lying between the PH and SH2 domains, amino acids 415-420, which is defined as a mutational hotspot (PMID: 22640988). There is a large physicochemical difference between proline and arginine. This variant is absent from gnomAD v2.1 and v3.1. This is the most commonly reported variant in families with a clinical diagnosis of Cherubism (PMID: 11381256, 22640988, 30236129). Functional assays demonstrate that the variant causes a gain-of-function by increasing the interaction with specific signalling molecules and a homozygous Sh3bp2 Pro416Arg knock-in mouse model recapitulates the human cherubism phenotype (PMID: 17218256, 20117257, 21794028). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (5/5 algorithms). Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as PATHOGENIC. Following criteria are met: PS3, PS4, PM1, PM2_Supporting, PP3. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 22, 2021 | Published functional studies demonstrate P418R causes gain of function by increasing interaction of B cells with specific signaling molecules (Lietman et al., 2006; Levaot et al., 2011; Ogi et al., 2011; Mukai et al., 2014); Not observed at significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22153077, 24916406, 21794028, 25144740, 16786512, 20691350, 11381256, 18596838, 14577811, 29669173, 30236129, 28904407, 22153076, 27498064) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 26, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at